Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents
Pembrolizumab: Rapidly moving the field forward through industry-academic collaborations
Date
10 Oct 2016Session
Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agentsPresenters
Paul HaluskaAuthors
P. HaluskaAuthor affiliations
- Global Center For Scientific Affairs, Merck, 07065 - Rahway/US
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Introduction
Presenter: Roger Stupp
Session: Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents
Resources:
Slides
Developing drugs targeting the PI3K/AKT signalling
Presenter: Li Yan
Session: Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents
Resources:
Slides
Novel clinical trial designs incorporating genomics for developing anti-cancer drugs: Olaparib in prostate cancer
Presenter: Johann de Bono
Session: Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents
Resources:
Slides
The role of consortia and corporative groups in the modern era of cancer drug development
Presenter: Roger Stupp
Session: Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents
Resources:
Slides